Synaptogenix announced a new partnership with Cannasoul Analytics in support of research and development of pharmaceutical therapeutics. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion – Israel Institute of Technology, and cannabis key opinion leader and researcher Professor Dedi Meiri from The Technion. Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and future products developed by Cannasoul and licensed from The Technion. Synaptogenix has approximately $33M in cash as of June 30. Founded in 1912, The Technion is Israel’s largest center of applied research and a major source of innovation driving the Israeli economy.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNPX:
- Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion – Israel Institute of Technology
- Synaptogenix’s Bryostatin-1 in Alzheimer’s featured in peer-reviewed publication
- Synaptogenix announces findings from independent study on Bryostatin-1
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue